Er Dong Hua
Directeur/Membre du Conseil chez Hua Medicine (Shanghai) Co., Ltd.
Profil
Er Dong Hua is currently a Director at Hua Medicine (Shanghai) Co., Ltd.
and a Partner at 6 Dimensions Capital since 2017.
He previously worked as a Partner at Frontline Bioventures.
Postes actifs de Er Dong Hua
| Sociétés | Poste | Début |
|---|---|---|
6 Dimensions Capital
 6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Private Equity Investor | 18/05/2017 |
Hua Medicine (Shanghai) Co., Ltd.
 Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Directeur/Membre du Conseil | - |
Anciens postes connus de Er Dong Hua
| Sociétés | Poste | Fin |
|---|---|---|
| Frontline Bioventures | Directeur/Membre du Conseil | 18/05/2017 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
| Frontline Bioventures | Finance |
6 Dimensions Capital
6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Finance |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Health Technology |
